Literature DB >> 9703518

Candidate vaccines for Epstein-Barr virus.

D J Moss, A Suhrbier, S L Elliott.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9703518      PMCID： PMC1113706          DOI： 10.1136/bmj.317.7156.423

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

Review 1.  Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

Review 2.  Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals.

Authors:  J A Thomas; M J Allday; D H Crawford
Journal:  Adv Cancer Res       Date:  1991       Impact factor: 6.242

Review 3.  Strategies involved in developing an effective vaccine for EBV-associated diseases.

Authors:  D J Moss; C Schmidt; S Elliott; A Suhrbier; S Burrows; R Khanna
Journal:  Adv Cancer Res       Date:  1996       Impact factor: 6.242

4.  Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.

Authors:  S A Thomson; M A Sherritt; J Medveczky; S L Elliott; D J Moss; G J Fernando; L E Brown; A Suhrbier
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

5.  Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV.

Authors:  M Mackett; C Cox; S D Pepper; J F Lees; B A Naylor; N Wedderburn; J R Arrand
Journal:  J Med Virol       Date:  1996-11       Impact factor: 2.327

Review 6.  Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.

Authors:  A B Rickinson; D J Moss
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

7.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Authors:  C M Rooney; C A Smith; C Y Ng; S Loftin; C Li; R A Krance; M K Brenner; H E Heslop
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

8.  First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen.

Authors:  S Y Gu; T M Huang; L Ruan; Y H Miao; H Lu; C M Chu; M Motz; H Wolf
Journal:  Dev Biol Stand       Date:  1995
  8 in total
  1 in total

1.  Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.

Authors:  Suzanne L Elliott; Andreas Suhrbier; John J Miles; Greg Lawrence; Stephanie J Pye; Thuy T Le; Andrew Rosenstengel; Tam Nguyen; Anthony Allworth; Scott R Burrows; John Cox; David Pye; Denis J Moss; Mandvi Bharadwaj
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.